Participants were randomly assigned either to escalation of dulaglutide to 4.5 mg or maximum tolerated dose (MTD), or to ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

For the current study, 139 patients were randomly assigned to tirzepatide 15 mg or a maximum tolerated ... and body weight was 96.9 kg (213.6 lb). Baseline dulaglutide dose was 1.5 mg once weekly ...

The original SURMOUNT-1 trial was published in NEJM in 2022, and found that, across 72 weeks, participants with obesity treated with 5 mg, 10 mg, or 15 mg of tirzepatide once weekly experienced ...

Medication doses were gradually increased to 15 mg for tirzepatide or 4.5 mg for dulaglutide, or to the highest maximum dose a participant could tolerate. The study’s primary and secondary ...

The original SURMOUNT-1 trial was published in NEJM in 2022, and found that, across 72 weeks, participants with obesity treated with 5 mg, 10 mg, or 15 mg of tirzepatide once weekly experienced ...

After a median follow-up of two years and a maximum of three years, cardiovascular death or worsening heart failure events occurred in 9.9% of the tirzepatide group and 15.3% of those taking placebo.

Among participants treated with tirzepatide 15 mg (N=224), 73%, 20%, and 7% experienced less than 5%, 5% to 10%, and 10% or more weight regain from nadir to Week 176, respectively. The authors ...